KEYMED BIOSCIENCES -0001 Net Assets
KEYMED BIOSCIENCES -0001 net assets. Based on the latest financial reports, KEYMED BIOSCIENCES -0001 (64Z) has net assets worth €2.77 Billion EUR (≈ $3.24 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€4.22 Billion ≈ $4.93 Billion USD) and total liabilities (€1.44 Billion ≈ $1.69 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore KEYMED BIOSCIENCES -0001 (64Z) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €2.77 Billion |
| % of Total Assets | 65.79% |
| Annual Growth Rate | -6.59% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 10.93 |
Net Assets of KEYMED BIOSCIENCES -0001 (2021–2025)
Net assets of KEYMED BIOSCIENCES -0001 from 2021 to 2025. This chart illustrates how KEYMED BIOSCIENCES -0001's net assets have evolved over time, based on quarterly financial data. See 64Z equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for KEYMED BIOSCIENCES -0001 (2021–2025)
The table below shows the annual net assets of KEYMED BIOSCIENCES -0001 from 2021 to 2025. For live market cap and overall valuation, see KEYMED BIOSCIENCES -0001 (64Z) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €2.77 Billion ≈ $3.24 Billion |
+12.11% |
| 2024-12-31 | €2.48 Billion ≈ $2.89 Billion |
-17.13% |
| 2023-12-31 | €2.99 Billion ≈ $3.49 Billion |
-10.55% |
| 2022-12-31 | €3.34 Billion ≈ $3.90 Billion |
-8.40% |
| 2021-12-31 | €3.65 Billion ≈ $4.26 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to KEYMED BIOSCIENCES -0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 283.2% over the analyzed period, potentially due to dividend distributions or operating losses.
KEYMED BIOSCIENCES -0001 Net Assets Breakdown (December 2025)
KEYMED BIOSCIENCES -0001 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €9.46 Billion | 341.05% |
| Total Equity | €2.77 Billion | 100.00% |
KEYMED BIOSCIENCES -0001 Competitors by Market Cap
The table below lists competitors of KEYMED BIOSCIENCES -0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Catena AB
ST:CATE
|
$2.57 Billion |
|
Warby Parker Inc
NYSE:WRBY
|
$2.57 Billion |
|
Hyundai Steel
KO:004020
|
$2.57 Billion |
|
Sai MicroElectronics Inc
SHE:300456
|
$2.57 Billion |
|
Bilfinger SE
XETRA:GBF
|
$2.57 Billion |
|
Peabody Energy Corp
NYSE:BTU
|
$2.56 Billion |
|
Ruentex Development Co Ltd
TW:9945
|
$2.56 Billion |
|
Colt CZ Group SE
PR:COLT
|
$2.56 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in KEYMED BIOSCIENCES -0001's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,474,571,000 to 2,774,254,000, a change of 299,683,000 (12.1%).
- Net loss of 522,641,000 reduced equity.
- New share issuances of 791,681,000 increased equity.
- Other factors increased equity by 30,643,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-522.64 Million | -18.84% |
| Share Issuances | €791.68 Million | +28.54% |
| Other Changes | €30.64 Million | +1.1% |
| Total Change | €- | 12.11% |
Book Value vs Market Value Analysis
This analysis compares KEYMED BIOSCIENCES -0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.79x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.57x to 0.79x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €13.05 | €7.45 | x |
| 2022-12-31 | €12.04 | €7.45 | x |
| 2023-12-31 | €10.80 | €7.45 | x |
| 2024-12-31 | €8.98 | €7.45 | x |
| 2025-12-31 | €9.42 | €7.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently KEYMED BIOSCIENCES -0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -18.84%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -72.96%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.52x
- Recent ROE (-18.84%) is above the historical average (-33.48%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -106.47% | -3525.30% | 0.03x | 1.08x | €-4.25 Billion |
| 2022 | -9.22% | -307.92% | 0.03x | 1.18x | €-642.14 Million |
| 2023 | -12.03% | -101.49% | 0.09x | 1.30x | €-657.99 Million |
| 2024 | -20.82% | -120.35% | 0.11x | 1.52x | €-762.70 Million |
| 2025 | -18.84% | -72.96% | 0.17x | 1.52x | €-800.07 Million |
Industry Comparison
This section compares KEYMED BIOSCIENCES -0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,369,067
- Average return on equity (ROE) among peers: -55.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| KEYMED BIOSCIENCES -0001 (64Z) | €2.77 Billion | -106.47% | 0.52x | $2.57 Billion |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $141.97 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $714.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About KEYMED BIOSCIENCES -0001
Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom. The company develops Kangyueda for the treatment of moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis;… Read more